title: Should circulating anticoagulant [AKA anti-phospholipid] assays be a routine component of well-patient assessment?
abstract: Circulating anticoagulants are a major risk factor for thrombotic problems (eg, myocardial infarction, stroke) and pregnancy complications. The authors present a retrospective survey of anticardiolipin antibody and lupus anticoagulant in 200 consecutive patients presenting to their office.
authors.affiliation: Foot and Ankle Clinic, Youngstown Osteopathic Hospital, Ohio, USA.
authors.forename: G
authors.initials: G
authors.lastname: Kubitz
authors.forename: B M
authors.initials: BM
authors.lastname: Rothschild
mesh_terms: D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000378:metabolism*; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000378:metabolism*; D008297:Male; D008403:Mass Screening; D011247:Pregnancy; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D017153:Antibodies, Anticardiolipin; D016682:Lupus Coagulation Inhibitor